Corbel Holdings, Inc. Announces That It Has Signed A Letter Of Intent With HaloLaser Biotherapy LLC, And Charles R. Crane MD And Associates Inc. To Merge

LAS VEGAS, Oct. 29 /PRNewswire-FirstCall/ -- Corbel Holdings, Inc. (Pink Sheets: CBLH) is pleased to announce that the company has signed a letter of intent with HaloLaser Biotherapy LLC, and Charles R. Crane MD and Associates Inc., to enter an agreement to facilitate a reverse merger of HaloLaser Biotherapy LLC and Charles R. Crane MD and Associates into Corbel, for purposes of taking control and functioning on its own merits and being identified as a legal trading company. From the date of this announcement, Corbel Holdings, Inc., HaloLaser Biotherapy LLC, and Charles R. Crane MD and Associates Inc. have a 30 day due diligence period before the closing of the transaction.

HaloLaser Biotheapry LLC together with Charles R. Crane MD and Associates Inc. in Dallas, Texas are in the biotech medical healthcare business of treating patients with acute pain and arthritis. Charles R. Crane MD and Associates Inc. has been in business since 1972. Dr. Crane is Board Certified in physical medicine. HaloLaser Pain Management & Wellness Clinic is the first clinic in the USA to treat acute muscle and skeletal pain with the new FDA approved Neurolase 150 Medical laser device subsequent to the FDA approval of the device. Dr. Charles R. Crane, President of Charles R. Crane MD and Associates stated, "It's exciting providing an opportunity to bring a new technology for pain relief and improve one's quality of life." Additional information on HaloLaser can be found on the Internet at http://www.halolaser.com/ .

Keith Houser, President and CEO of HaloLaser Biotherapy LLC, stated, "This merger opportunity will facilitate the expeditious expansion of Pain Management and Wellness centers across the United States utilizing the Neurolase 150 Medical Laser."

Bruce Harlan, President and CEO of Corbel Holdings, Inc., stated, "We have been looking for a merger candidate of this quality for quite some time. We are very excited with the prospects of this merger to bring increased value to our shareholders."

Safe Harbor:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the Company to complete the planned bridge financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing and other risks described in the Company's SEC reports and filings.

ON BEHALF OF THE BOARD of Corbel Holdings, Inc., HaloLaser Biotherapy LLC and Charles R. Crane MD Medical Clinic

Corbel Holdings, Inc.

CONTACT: Bruce Harlan of Corbel Holdings, +1-702-326-2805; or KeithHouser of HaloLaser Biotherapy LLC and Charles R. Crane, MD, 800-200-2458

MORE ON THIS TOPIC